Puretech Health (PRTC) Fundamental Analysis: Revenue, Earnings & Valuation

2.84 / 10

Underperform

Fundamental analysis rates PureTech as Underperform (2.8/10). Strengths include solid current‑liabilities ratio and interest coverage, but long‑term debt to working capital and high cost‑of‑sales hurt the picture. Overall, the low 2.84 fund score reflects weak earnings growth and margin pressure.

Analysis Checks(6/7)

Total operating revenue (YoY growth rate %)

Value542.71

Score2/3

Weight-3.94%

1M Return0.13%

Inventory turnover ratio

Value37.77

Score2/3

Weight32.69%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value22.03

Score2/3

Weight-11.08%

1M Return0.36%

Long-term debt to working capital ratio (%)

Value0.47

Score1/3

Weight19.27%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value27.69

Score2/3

Weight33.24%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value542.71

Score2/3

Weight-1.59%

1M Return0.05%

Cost of sales ratio (%)

Value73.08

Score2/3

Weight31.42%

1M Return-1.13%

Is PRTC fundamentally strong?

PRTC scores 2.84/10 on fundamentals and holds a Premium valuation at present. Backed by its -11.48% ROE, 498.89% net margin, 7.36 P/E ratio, 1.01 P/B ratio, and 156.67% earnings growth, these metrics solidify its Underperform investment rating.